Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Int J Hematol. 2019 Jul;110(1):115-118. doi: 10.1007/s12185-019-02622-0. Epub 2019 Apr 13.
Autologous stem-cell transplantation is an effective procedure for the treatment of multiple myeloma, and involves the collection of hematopoietic stem cells (HSCs). However, in some patients, HSCs in the bone marrow fail to mobilize. Pomalidomide upregulates CXCR4 in hematopoietic stem cells, in a manner similar to that of lenalidomide, and is, thus, likely to have a negative impact on hematopoietic stem-cell mobilization in multiple myeloma patients. Here, we report the two cases in which hematopoietic stem cells were mobilized using plerixafor plus granulocyte-colony stimulating factor after exposure to lenalidomide and pomalidomide. Use of plerixafor with a sufficient washout period may lead to successful mobilization following pomalidomide use, although further study of this potential use is needed.
自体干细胞移植是治疗多发性骨髓瘤的有效方法，涉及采集造血干细胞（HSCs）。然而，在一些患者中，骨髓中的 HSCs 无法动员。泊马度胺以类似于来那度胺的方式上调造血干细胞中的 CXCR4，因此可能对多发性骨髓瘤患者造血干细胞动员产生负面影响。在这里，我们报告了两例在接受来那度胺和泊马度胺治疗后使用培洛昔芬联合粒细胞集落刺激因子动员造血干细胞的病例。使用培洛昔芬并充分清洗后，可能会导致在使用泊马度胺后成功动员，尽管需要进一步研究这种潜在用途。
